Matches in Wikidata for { <http://www.wikidata.org/entity/Q37614989> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- Q37614989 description "article científic" @default.
- Q37614989 description "article scientifique" @default.
- Q37614989 description "articolo scientifico" @default.
- Q37614989 description "artigo científico" @default.
- Q37614989 description "artículu científicu espublizáu en 2009" @default.
- Q37614989 description "bilimsel makale" @default.
- Q37614989 description "scientific article published on October 2009" @default.
- Q37614989 description "vedecký článok" @default.
- Q37614989 description "vetenskaplig artikel" @default.
- Q37614989 description "videnskabelig artikel" @default.
- Q37614989 description "vědecký článek" @default.
- Q37614989 description "wetenschappelijk artikel" @default.
- Q37614989 description "wissenschaftlicher Artikel" @default.
- Q37614989 description "наукова стаття, опублікована в жовтні 2009" @default.
- Q37614989 description "научни чланак" @default.
- Q37614989 description "مقالة علمية نشرت في أكتوبر 2009" @default.
- Q37614989 name "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 name "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 name "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 type Item @default.
- Q37614989 label "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 label "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 label "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 prefLabel "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 prefLabel "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 prefLabel "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 P1433 Q37614989-4005EDA1-EED5-486B-8026-DACFDA515230 @default.
- Q37614989 P1476 Q37614989-DF5EB7B1-8BC5-43C3-9BE1-6FD05121F20E @default.
- Q37614989 P2093 Q37614989-1D5E2A69-F54A-4A32-AD86-C81CD7DC5BC8 @default.
- Q37614989 P2093 Q37614989-3661B34D-FF51-4B65-8689-8A5B8A945764 @default.
- Q37614989 P2093 Q37614989-BBC4364B-D3FA-4C81-9235-476B65B63E80 @default.
- Q37614989 P2860 Q37614989-0A1A2D24-622A-407D-A2F8-C82120F18CBA @default.
- Q37614989 P2860 Q37614989-0BD58671-6C05-4DE6-84C6-D763FFBF1D9A @default.
- Q37614989 P2860 Q37614989-1C05FDC3-9F33-4C5E-97DB-73613B1A6AED @default.
- Q37614989 P2860 Q37614989-25F1726C-1162-4FB6-AA97-A60A8E15617E @default.
- Q37614989 P2860 Q37614989-504E4710-486C-42B0-B306-A67B01E93FAA @default.
- Q37614989 P2860 Q37614989-59DA57F7-45D2-479C-B5B9-01716BFD5BB0 @default.
- Q37614989 P2860 Q37614989-5B4E94A1-609F-4203-A0F5-E392540FFFAD @default.
- Q37614989 P2860 Q37614989-6B8F85B8-3A2C-4FF4-94B4-065541D41E4C @default.
- Q37614989 P2860 Q37614989-8C183D5E-698B-4AF5-96C0-33C748B4125A @default.
- Q37614989 P2860 Q37614989-9006B966-B6DE-469E-BAC5-08AD67A8E416 @default.
- Q37614989 P2860 Q37614989-A989F44A-D06B-480A-9B13-D87BE6DF9931 @default.
- Q37614989 P2860 Q37614989-AD3859CB-03F7-4927-93B5-848987154CA0 @default.
- Q37614989 P2860 Q37614989-F3D45290-5F0F-4A88-9894-E49151BFB153 @default.
- Q37614989 P304 Q37614989-BB1EBA88-5EF5-4E85-95D6-EBCE0DED6AF9 @default.
- Q37614989 P31 Q37614989-B31E67A5-D17E-4335-A3E6-5592140675EB @default.
- Q37614989 P356 Q37614989-BBB49EAD-5CBB-4327-91BD-B845EFE1E3F7 @default.
- Q37614989 P433 Q37614989-C79C6FAF-467A-4621-AA87-D2E09C36221F @default.
- Q37614989 P478 Q37614989-E1D80207-FB36-488B-89B9-E00053D6B01F @default.
- Q37614989 P577 Q37614989-78681678-0CC1-4076-91F8-2C7D95F2B325 @default.
- Q37614989 P698 Q37614989-61CA7EC3-F7E8-4EEC-B463-ACD7734BD9ED @default.
- Q37614989 P921 Q37614989-43B47F38-9289-4599-93B5-0899B05A5C3B @default.
- Q37614989 P921 Q37614989-D4294298-BA63-483C-B957-1E4538498893 @default.
- Q37614989 P921 Q37614989-DA24E8B4-B748-4167-A05F-0934A6208D5F @default.
- Q37614989 P932 Q37614989-D965B507-B997-42F3-9808-6AF3BC314F34 @default.
- Q37614989 P356 CUAJ.1145 @default.
- Q37614989 P698 19829727 @default.
- Q37614989 P1433 Q26842808 @default.
- Q37614989 P1476 "A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer" @default.
- Q37614989 P2093 "Mikael Hanninen" @default.
- Q37614989 P2093 "Peter Venner" @default.
- Q37614989 P2093 "Scott North" @default.
- Q37614989 P2860 Q29616123 @default.
- Q37614989 P2860 Q29616218 @default.
- Q37614989 P2860 Q33767866 @default.
- Q37614989 P2860 Q35211257 @default.
- Q37614989 P2860 Q36607936 @default.
- Q37614989 P2860 Q39413134 @default.
- Q37614989 P2860 Q43784087 @default.
- Q37614989 P2860 Q43889923 @default.
- Q37614989 P2860 Q72078080 @default.
- Q37614989 P2860 Q73287845 @default.
- Q37614989 P2860 Q73287848 @default.
- Q37614989 P2860 Q74545980 @default.
- Q37614989 P2860 Q80970864 @default.
- Q37614989 P304 "369-374" @default.
- Q37614989 P31 Q13442814 @default.
- Q37614989 P356 "10.5489/CUAJ.1145" @default.
- Q37614989 P433 "5" @default.
- Q37614989 P478 "3" @default.
- Q37614989 P577 "2009-10-01T00:00:00Z" @default.
- Q37614989 P698 "19829727" @default.
- Q37614989 P921 Q181257 @default.
- Q37614989 P921 Q420436 @default.
- Q37614989 P921 Q974135 @default.
- Q37614989 P932 "2758517" @default.